Cardiac amyloidosis medical therapy

	Cardiac amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cardiac Amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cardiac amyloidosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiac amyloidosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac amyloidosis medical therapy
CDC onCardiac amyloidosis medical therapy
Cardiac amyloidosis medical therapy in the news
Blogs on Cardiac amyloidosis medical therapy
Directions to Hospitals Treating Cardiac amyloidosis
Risk calculators and risk factors for Cardiac amyloidosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]; Cafer Zorkun, M.D., Ph.D. [4]; Lakshmi Gopalakrishnan, M.B.B.S. [5]

Overview

Diuretics and angiotensin-converting inhibitors are the standard therapy regimen to treat congestive heart failure secondary to cardiac amyloidosis. However, presence of hypotension may limit the use of diuretics

Digoxin and calcium channel blockers bind to the amyloid fibrils and thereby have been reported to increase the incidence of congestive heart failure and produce arrhythmias. Hence, these drugs may be avoided in patients with both AL and TTR cardiac amyloidosis.^[1]^[2]^[3]

A pacemaker may be needed if the conduction system is involved.

Physical activity may continue as long as the patient can tolerate it.

Diet restrictions vary with the extent of cardiomyopathy and heart failure. These may include salt and/or fluid restrictions.

↑ Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA (1985). "Selective binding of nifedipine to amyloid fibrils". The American Journal of Cardiology. 55 (13 Pt 1): 1646. PMID 4003315. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
↑ Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA (1985). "Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents". The American Journal of Cardiology. 55 (13 Pt 1): 1645. PMID 4003314. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
↑ Rubinow A, Skinner M, Cohen AS (1981). "Digoxin sensitivity in amyloid cardiomyopathy". Circulation. 63 (6): 1285–8. PMID 7014028. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
↑ Mathew V, Olson LJ, Gertz MA, Hayes DL (1997). "Symptomatic conduction system disease in cardiac amyloidosis". The American Journal of Cardiology. 80 (11): 1491–2. PMID 9399732. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
↑ Mathew V, Chaliki H, Nishimura RA (1997). "Atrioventricular sequential pacing in cardiac amyloidosis: an acute Doppler echocardiographic and catheterization hemodynamic study". Clinical Cardiology. 20 (8): 723–5. PMID 9259166. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)